MTOR and hyperlipidemia: Hyperlipidemia, peroxisome proliferator-activated receptor (PPAR) alpha/delta agonist drugs, butyrate (149), and other metabolic changes in obesity reduce the function of mammalian target of rapamycin (mTOR) and NK cytotoxicity in vivo and in vitro (150).